Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T11:30:19.896Z Has data issue: false hasContentIssue false
  • English
  • Français

Therapy of Ocular Herpes Simplex Infections

Published online by Cambridge University Press:  02 January 2015

Mark Eggleston
Mark Eggleston*
Affiliation:
College of Pharmacy, Howard University, Washington, DC
*
PO Box 115, Wood-bridge, VA 22191
Get access Rights & Permissions [Opens in a new window]

Extract

Herpes simplex viral infection is a common cause of infection involving the eye and skin adjacent to the eye. Acute keratoconjunctivitis is a frequently observed herpetic manifestation often accompanied or exacerbated by stress factors, including fever (especially when associated with respiratory or intestinal infection), stress, trauma, environmental exposure, drugs, and menstruation. Each year approximately 300,000 to 500,000 cases of corneal herpes are reported. Complications such as decreased or lost vision may be associated with attacks of ophthalmic herpes infections. Therefore, effective treatment is imperative.1 Experts estimate that nearly 25% of patients with a primary ocular infection will have a recurrence of the infection, and approximately 50% of these patients will have a recurrence within two years. Herpes viral infections are a significant cause of blindness and a primary indication for corneal transplants.

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 8 , Issue 7 , July 1987 , pp. 294 - 296
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Kaufman, HE, Herpetic keratitis. Invest Ophthalmol Vis Sei 1978;17(10):941.Google Scholar
2.Pavan-Langston, DROcular viral diseases, in Galasso, GJ, Merigan, TC, Buchanan, RA (eds): Antiviral Agents and Viral Diseases of Man. New York, Raven Press, 1979, pp 253–303.Google Scholar
3.Kaplan, AS, Ben-Porat, TLMode of antiviral action of 5-iodouracil deoxy-riboside. J Mol Biol 19:320.CrossRefGoogle Scholar
4.Mastan, PF, Henderson, JW, Penetration of idoxuridine into the anterior segment after transdermal or subconjunctival injection. Invest Ophthalmol 1966;5:320.Google Scholar
5.Dawson, CR, Toyin, BA, Herpes simplex eye infections: Clinical manifestations, pathogenesis and management. Surv Ophthalmol 1976;21:121.Google Scholar
6.Kaufman, HE, Antimetabolite drug therapy in herpes simplex. Ophthalmol 1980;87(2):135.Google Scholar
7.Mueller, WE, Mechanisms of action and pharmacology: Chemical agents, in Galasso, GJ, Merigan, TC, Buchanan, RA (eds): Antiviral Agents and Viral Diseases of Man. New York, Raven Press, 1979, pp 77–149.Google Scholar
8.Pavan-Langston, DRHess, F, Ocular and systemic antiviral activity of vid-arabine. Compr Ther 1977;3:42.Google Scholar
9.Bauer, DJ, Collins, P, Tucker, WE, et al: Treatment of experimental herpes simplex keratitis with acycloguanosine. Br J Ophthalmol 1979;63:429.Google Scholar
10.Pavan-Langston, DRDohlman, CH, A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis. Am J Ophthalmol 1972;78:81.CrossRefGoogle Scholar
11.Abel, R, Kaufman, HE, Sugar, J, Intravenous adenosine arabinoside against herpes simplex keratouveitis in humans. Am J Ophthalmol 1975;79:659.CrossRefGoogle Scholar
12.Pavan-Langston, DRFoster, CS, Trifiuorothymidine and idoxuridine therapy of ocular herpes. Am J Ophthalmol 1979;84:818.CrossRefGoogle Scholar
13.Kaufman, HE, Antiviral update. Ophthalmology 1979;86:131–136.CrossRefGoogle ScholarPubMed
14.McGiu, J, Some aspects of the clinical use of trifiuorothymidine in the treatment of herpetic ulceration of the cornea. Trans Ophthalmol Soc UK 1974;94:342.Google Scholar
15.Fyfe, JA, Keller, PM, Furman, PA, et al: Thymidine kinase from herpes simplex virus phosphorylates: The new antiviral compound, 9-(2-hydroxyethox-ymethyl) guanine. J Biol Chem 1978;253:8721.Google Scholar
16.Elion, GB, Furman, PA, Fyfe, JA, et al: Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci USA 1977;74(12):5716.Google Scholar
17.Pavan-Langston, DRCampbell, R, Lass, J, Acyclic antimetabolite therapy of experimental herpes simplex keratitis. Am J Ophthalmol 1978;86:618.Google Scholar
18.Jones, BR, Coster, DJ, Fison, PN, et al: Efficacy of acycloguanosine (Wellcome 248u) against herpes simplex corneal ulcers. Lancet 1979;1:243.Google Scholar